ClinicalTrials.gg
RecruitingNCT07696572Updated Oct 20, 2026

EUS Procedures Using RIVOS™ EUS Access Device

An observational study in Pancreatic Fluid Collections, Biliary Obstruction and Pancreatic Duct Obstruction, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Orlando Health, Inc. · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.

Planned enrollment
34th of 38
30 · median 167
Started
2026
with 7 others
Observational
38 of 111
10 open now
Primary completion
2027-07
later than 19 of 37 live
Registered
109th of 111
by date

Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 34th largest by planned enrollment of the 38 observational ones that give a count, is one of 8 that started in 2026, is one of 38 observational ones, reaches primary completion later than 19 of the 37 other live ones, and was the 109th registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Pancreatitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.

Read the detailed description

Endoscopic ultrasound (EUS)-guided interventions are becoming the first-line treatment of various pancreaticobiliary disorders such as malignant biliary obstruction, access to bile duct or pancreatic duct after failed ERCP, and drainage of pancreatic, peripancreatic or intraabdominal fluid collections. However, given the lack of dedicated devices for performing these complex interventions, accessories used to perform endoscopic retrograde cholangiopancreatography (ERCP) are currently being used off-label to perform most interventional EUS procedures.

The RIVOS™ EUS access device is a novel, FDA approved device that has been specifically developed for performing EUS-guided interventions. The device has a sharp trocar tip to allow access to the target organ, a flexible access cannula to allow contrast injection and passage of a guidewire, and an electrocautery-tip to facilitate the creation of a fistula. This innovative design is expected to simplify the technical aspects of the procedure and improve the safety profile for these complex endoscopic interventions.

The aim of this study is to evaluate the technical and treatment outcomes in patients undergoing standard of care, interventional EUS-guided procedures in patients with pancreaticobiliary disorders using the RIVOS™ EUS access device.

03

Conditions studied

  • Pancreatic Fluid Collections
  • Biliary Obstruction
  • Pancreatic Duct Obstruction
  • Chronic Pancreatitis
  • Pancreatic Cancer Non-resectable

Browse trials for

Keywords

  • EUS-guided bile duct drainage
  • EUS-guided pancreatogastrostomy
  • Endoscopic ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing EUS-guided interventions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • All patients undergoing EUS-guided interventions using the RIVOS™ EUS access device

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients who did not undergo EUS-guided interventions using the RIVOS™ EUS access device
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
4 Weeks
Patient registry
Yes

Groups and cohorts

  • Patients requiring interventional EUS procedures

    Patients requiring interventional EUS procedures

    Device: EUS-guided intervention using the RIVOS™ EUS access device

Interventions

  • DeviceEUS-guided intervention using the RIVOS™ EUS access device

    EUS-guided intervention using the RIVOS™ EUS access device

06

What researchers measure

Primary outcomes

  1. Technical success

    Rate of technical success in patients undergoing EUS-guided procedures

    Time frame: 1 day

Secondary outcomes

  1. Treatment success

    Rate of treatment success, defined as the resolution of symptoms and/or radiological findings from underlying disease at 4-weeks following index intervention.

    Time frame: 4 weeks

  2. Adverse events

    Rate of adverse events, procedure-related and disease-related, in patients undergoing endoscopic ultrasound procedures.

    Time frame: 4 weeks

  3. Procedure duration

    Total procedure duration, defined as time taken from start of the EUS-procedure to time the echoendoscope is withdrawn from the patient.

    Time frame: 1 day

  4. Hospital admission

    Rate of hospital admission due to disease-related symptoms or procedure-related adverse events.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 12 months is below that.

Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07696572
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 13, 2026
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Ji Young Bang, MD MPH
Contact
jiyoung.bang@orlandohealth.com
321-842-2273
Barbara J Broome
Contact
barbara.broome@orlandohealth.com
321-841-3742

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion